Patents by Inventor William Henry Miller

William Henry Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6825188
    Abstract: Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: November 30, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: James Francis Callahan, Russell Donovan Cousins, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Irene Nijole Uzinskas
  • Publication number: 20040082559
    Abstract: Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.
    Type: Application
    Filed: October 22, 2003
    Publication date: April 29, 2004
    Applicant: SmithKline Beecham Corporation
    Inventors: James Francis Callahan, Russell Donovan Cousins, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Irene Nijole Uzinskas
  • Publication number: 20030125317
    Abstract: Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.
    Type: Application
    Filed: December 16, 2002
    Publication date: July 3, 2003
    Applicant: SmithKline Beecham Corporation
    Inventors: James Francis Callahan, Russell Donovan Cousins, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Irene Nijole Uzinskas
  • Patent number: 6458784
    Abstract: Pharmaceutically active benzodiazapine compounds of formula (I) are disclosed. These compounds inhibit the vitronectin receptor and are useful for treatment of osteoporosis.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: October 1, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Russell Donovan Cousins, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Irene Nijole Uzinskas
  • Patent number: 6069143
    Abstract: This invention relates to compounds of the formula: ##STR1## which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: May 30, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: Fadia El-Fehail Ali, William Edward Bondinell, Raul Rolando Calvo, Thomas Wen-Fu Ku, William Henry Miller, James Samanen, Joseph Walter Venslavsky, Tobias Oregon Yellin
  • Patent number: 6060462
    Abstract: This invention relates to electrophilic dipeptide analogs conjugated to an N,N-disubstituted .alpha.-amino acid as inhibitors of trypsin-like serine protease enzymes.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: May 9, 2000
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Robert Anthony Galemmo, Jr., Matthew Mark Abelman, Eugene Cruz Amparo, John Matthew Fevig, Robert Madara Knabb, William Henry Miller, Gregory James Pacofsky, Patricia Carol Weber, Joseph Cacciola
  • Patent number: 6008214
    Abstract: This invention relates to compounds of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, which are effective for inhibiting platelet aggregation and bone resorption, pharmaceutical compositions for effecting such activity, and a method for using these compounds.
    Type: Grant
    Filed: February 18, 1997
    Date of Patent: December 28, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Chet Kwon, William Henry Miller
  • Patent number: 5977101
    Abstract: Vitronectin receptor antagonists having the formula: ##STR1## which are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporsis.
    Type: Grant
    Filed: December 20, 1996
    Date of Patent: November 2, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Fadia El-Fehail Ali, William Bondinell, William Francis Huffman, M. Amparo Lago, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Thomas Nguyen, Dennis T. Takata
  • Patent number: 5741804
    Abstract: This invention relates to compounds of the formula: ##STR1## which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: April 21, 1998
    Assignee: SmithKline Beecham Corporation
    Inventors: Richard McCulloch Keenan, William Henry Miller
  • Patent number: 5698538
    Abstract: Novel boronic acid and ester and carboxyl-modified amino acid compounds of the Formula I, which are inhibitors of trypsin-like enzymes, are disclosed :R.sup.1 --Z--CHR.sup.2 --A,where R.sup.1, Z, R.sup.2 arid A are defined within.
    Type: Grant
    Filed: July 26, 1996
    Date of Patent: December 16, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Eugene Cruz Amparo, William Henry Miller, Gregory James Pacofsky, John Wityak, Patricia Carol Weber, John Jonas Vytautas Duncia, Joseph Basil Santella, III